Search research articles
Contact Us
Filters
Showing results (401-410 of 455) with videos related to
Page
of 46
Sort By:
Breast Cancer Research : BCR
|
November 10, 2016
Impact of CYP19A1 and ESR1 variants on early-onset side effects during combined endocrine therapy in the TEXT trial
Harriet Johansson, Kathryn P Gray, Olivia Pagani, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
March 12, 2008
Letrozole compared with tamoxifen for elderly patients with endocrine-responsive early breast cancer: the BIG 1-98 trial
Diana Crivellari, Zhuoxin Sun, Alan S Coates, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
February 16, 2007
Predictors of early relapse in postmenopausal women with hormone receptor-positive breast cancer in the BIG 1-98 trial
L Mauriac, A Keshaviah, M Debled, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
February 22, 2011
Which patients benefit most from adjuvant aromatase inhibitors? Results using a composite measure of prognostic risk in the BIG 1-98 randomized trial
G Viale, M M Regan, P Dell'Orto, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
November 2, 2011
Disease-related outcomes with long-term follow-up: an updated analysis of the intergroup exemestane study
Judith M Bliss, Lucy S Kilburn, Robert E Coleman, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
March 1, 2005
Site of primary tumor has a prognostic role in operable breast cancer: the international breast cancer study group experience
Marco Colleoni, David Zahrieh, Richard D Gelber, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
July 28, 2009
Adverse prognostic value of peritumoral vascular invasion: is it abrogated by adequate endocrine adjuvant therapy? Results from two International Breast Cancer Study Group randomized trials of chemoendocrine adjuvant therapy for early breast cancer
G Viale, A Giobbie-Hurder, B A Gusterson, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
March 20, 2008
Chemoendocrine compared with endocrine adjuvant therapies for node-negative breast cancer: predictive value of centrally reviewed expression of estrogen and progesterone receptors--International Breast Cancer Study Group
Giuseppe Viale, Meredith M Regan, Eugenio Maiorano, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
December 1, 2000
Identifying breast cancer patients at high risk for bone metastases
M Colleoni, A O'Neill, A Goldhirsch, et al.
British Journal of Cancer
|
June 28, 2002
Duration of adjuvant chemotherapy for breast cancer: a joint analysis of two randomised trials investigating three versus six courses of CMF
M Colleoni, H J Litman, M Castiglione-Gertsch, et al.
Page
of 46
Search research articles
Search
Showing results (401-410 of 455) with videos related to
Sort By:
Page
of 46
Breast Cancer Research : BCR
|
November 10, 2016
Impact of CYP19A1 and ESR1 variants on early-onset side effects during combined endocrine therapy in the TEXT trial
Harriet Johansson, Kathryn P Gray, Olivia Pagani, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
March 12, 2008
Letrozole compared with tamoxifen for elderly patients with endocrine-responsive early breast cancer: the BIG 1-98 trial
Diana Crivellari, Zhuoxin Sun, Alan S Coates, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
February 16, 2007
Predictors of early relapse in postmenopausal women with hormone receptor-positive breast cancer in the BIG 1-98 trial
L Mauriac, A Keshaviah, M Debled, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
February 22, 2011
Which patients benefit most from adjuvant aromatase inhibitors? Results using a composite measure of prognostic risk in the BIG 1-98 randomized trial
G Viale, M M Regan, P Dell'Orto, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
November 2, 2011
Disease-related outcomes with long-term follow-up: an updated analysis of the intergroup exemestane study
Judith M Bliss, Lucy S Kilburn, Robert E Coleman, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
March 1, 2005
Site of primary tumor has a prognostic role in operable breast cancer: the international breast cancer study group experience
Marco Colleoni, David Zahrieh, Richard D Gelber, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
July 28, 2009
Adverse prognostic value of peritumoral vascular invasion: is it abrogated by adequate endocrine adjuvant therapy? Results from two International Breast Cancer Study Group randomized trials of chemoendocrine adjuvant therapy for early breast cancer
G Viale, A Giobbie-Hurder, B A Gusterson, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
March 20, 2008
Chemoendocrine compared with endocrine adjuvant therapies for node-negative breast cancer: predictive value of centrally reviewed expression of estrogen and progesterone receptors--International Breast Cancer Study Group
Giuseppe Viale, Meredith M Regan, Eugenio Maiorano, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
December 1, 2000
Identifying breast cancer patients at high risk for bone metastases
M Colleoni, A O'Neill, A Goldhirsch, et al.
British Journal of Cancer
|
June 28, 2002
Duration of adjuvant chemotherapy for breast cancer: a joint analysis of two randomised trials investigating three versus six courses of CMF
M Colleoni, H J Litman, M Castiglione-Gertsch, et al.
Page
of 46